A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

被引：138

作者：

Barosi, Giovanni ^{[1
,2
]}

Birgegard, Gunnar ^{[3
]}

Finazzi, Guido ^{[4
]}

Griesshammer, Martin ^{[5
]}

Harrison, Claire ^{[6
]}

Hasselbalch, Hans ^{[7
]}

Kiladijan, Jean-Jacques ^{[8
]}

Lengfelder, Eva ^{[9
]}

Mesa, Ruben ^{[10
]}

Mc Mullin, Mary F. ^{[11
]}

Passamonti, Francesco ^{[12
]}

Reilly, John T. ^{[13
]}

Vannucchi, Alessandro M. ^{[14
]}

Barbui, Tiziano ^{[4
]}

机构：

[1] IRCCS, Policlin S Matteo Fdn Pavia, Clin Epidemiol Unit, Pavia, Italy

[2] IRCCS, Policlin S Matteo Fdn Pavia, Ctr Study Myelofibrosis, Pavia, Italy

[3] Univ Uppsala Hosp, Dept Haematol, Uppsala, Sweden

[4] Osped Riuniti Bergamo, Dept Haematol, I-24100 Bergamo, Italy

[5] Univ Hannover, Dept Haematol & Oncol, Johannes Wesling Med Ctr Minden, Acad Hosp, D-32429 Minden, Germany

[6] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England

[7] Roskilde Hosp, Dept Oncol Haematol, Roskilde, Denmark

[8] Univ Paris 07, Hop St Louis, AP HP, Ctr Invest Clin, Paris, France

[9] Univ Heidelberg, Fac Med Mannheim, Dept Med 3, D-6900 Heidelberg, Germany

[10] Mayo Clin, Div Hematol Oncol, Scottsdale, AZ 85259 USA

[11] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland

[12] Univ Pavia, Fdn IRCCS, Policlin San Matteo, Div Haematol, I-27100 Pavia, Italy

[13] Royal Hallamshire Hosp, Div Mol & Genet Med, Mol Haematol Unit, Sheffield S10 2JF, S Yorkshire, England

[14] Univ Florence, Unita Funz Ematol, Dipartimento Area Crit Med Chirurg, Florence, Italy

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2010年 / 148卷 / 06期

关键词：

polycythaemia vera; primary myelofibrosis; hydroxycarbamide; resistance; intolerance; ESSENTIAL THROMBOCYTHEMIA; RESPONSE CRITERIA; HYDROXYUREA; ANAGRELIDE; DISORDERS; THERAPY;

D O I：

10.1111/j.1365-2141.2009.08019.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：961 / 963

页数：3

共 10 条

[1] When and how to treat essential thrombocythemia [J].

Barbui, T ;

Finazzi, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (01) :85-86

[2] A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group [J].

Barosi, G. ;

Besses, C. ;

Birgegard, G. ;

Briere, J. ;

Cervantes, F. ;

Finazzi, G. ;

Gisslinger, H. ;

Griesshammer, M. ;

Gugliotta, L. ;

Harrison, C. ;

Hasselbalch, H. ;

Lengfelder, E. ;

Reilly, J. T. ;

Michiels, J. J. ;

Barbui, T. .

LEUKEMIA, 2007, 21 (02) :277-280

[3] Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET) [J].

Barosi, G ;

Bordessoule, D ;

Briere, J ;

Cervantes, F ;

Demory, JL ;

Dupriez, B ;

Gisslinger, H ;

Griesshammer, M ;

Hasselbalch, H ;

Kusec, R ;

Le Bousse-Kerdiles, MC ;

Liberato, NL ;

Marchetti, M ;

Reilly, JT ;

Thiele, J .

BLOOD, 2005, 106 (08) :2849-2853

[4] Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference [J].

Barosi, Giovanni ;

Birgegard, Gunnar ;

Finazzi, Guido ;

Griesshammer, Martin ;

Harrison, Claire ;

Hasselbalch, Hans Carl ;

Kiladjian, Jean-Jacques ;

Lengfelder, Eva ;

McMullin, Mary Frances ;

Passamonti, Francesco ;

Reilly, John T. ;

Vannucchi, Alessandro M. ;

Barbui, Tiziano .

BLOOD, 2009, 113 (20) :4829-4833

[5] Hydroxyurea and Anagrelide Combination Therapy in Patients with Chronic Myeloproliferative Diseases Resistant or Intolerant to Monotherapy [J].

Christoforidou, A. ;

Pantelidou, D. ;

Anastasiadis, A. ;

Goutzouvelidis, A. ;

Margaritis, D. ;

Kotsianidis, I. ;

Spanoudakis, E. ;

Kaloutsi, V. ;

Bourikas, G. ;

Tsatalas, C. .

ACTA HAEMATOLOGICA, 2008, 120 (04) :195-198

[6] A critical review of anagrelide therapy in essential thrombocythemia and related disorders [J].

Dingli, D ;

Tefferi, A .

LEUKEMIA & LYMPHOMA, 2005, 46 (05) :641-650

[7] Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia [J].

Harrison, CN ;

Campbell, PJ ;

Buck, G ;

Wheatley, K ;

East, CL ;

Bareford, D ;

Wilkins, BS ;

van der Walt, JD ;

Reilly, JT ;

Grigg, AP ;

Revell, P ;

Woodcock, BE ;

Green, AR ;

Pearson, TC ;

Conneally, E ;

Crawley, C ;

Cross, NCP ;

Hall, G ;

Hunt, B ;

Lucas, G ;

Ludlam, C ;

McMullin, MF ;

Oscier, D ;

Radia, D ;

Reilly, JT ;

Robinson, G ;

Culligan, DJ ;

Tighe, J ;

Watson, HG ;

Warren, AJ ;

Awaad, MO ;

Obeid, D ;

Cuthbert, RJG ;

Kyle, A ;

Chan-Lam, D ;

Paul, B ;

Cuthbert, RJG ;

McMullin, MF ;

Morris, TCM ;

Johnson, RJ ;

Fegan, C ;

Milligan, DW ;

Galloway, MJ ;

Williamson, PJ ;

Newton, LJ ;

Williams, AT ;

Abboudi, Z ;

Ryan, K ;

Lush, R ;

Blundell, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (01) :33-45

[8] Long-term incidence of hematological evolution in three french prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia [J].

Kiladjian, Jean-Jacques ;

Rain, Jean-Didier ;

Bernard, Jean-Francois ;

Briere, Jean ;

Chomienne, Christine ;

Fenaux, Pierre .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (04) :417-421

[9]

Randi ML, 2005, HAEMATOLOGICA, V90, P261

[10]

TEFFERI A, 1995, SEMIN ONCOL, V22, P334

← 1 →